AVITA Medical (NASDAQ:RCEL) announced on Tuesday, April 14, 2026, positive interim results from its Cohealyx-I clinical study, demonstrating that its dermal matrix significantly accelerates the timeline for skin grafting in complex wounds.
The data revealed a mean time to graft of 13.6 days, representing a nearly 20-day reduction compared to established literature benchmarks.
The interim analysis, which included 40 patients, established the statistical superiority of the treatment with a p-value of less than 0.001.
When measured against a 33.2-day benchmark derived from existing clinical literature, the Cohealyx-I results indicate a substantial improvement in the speed of wound bed preparation.
The study further highlighted that the median time to graft was 11 days, with some patients reaching the grafting stage as early as five days post-treatment.
Clinical performance metrics from the trial showed that 72% of participating patients were successfully grafted within 14 days.
This accelerated timeline was met with high levels of professional approval, as the company reported a 90% investigator satisfaction rate regarding the quality of the vascularized tissue bed.
The ability to expedite definitive wound closure is viewed as a critical factor in reducing hospital stay durations and improving overall patient recovery trajectories in burn and trauma care.
AVITA Medical remains on track to complete the study, with a full dataset expected to be released later in 2026.